HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma.

AbstractAIM:
Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the seventh in women. HCC varies widely in incidence through the world, with rising incidence in Egypt. This study aimed to estimate the serum levels of matrix metalloproteinase-9 (MMP-9) and its substrate galectin-3 in order to evaluate their diagnostic accuracy and their relation to HCC-related clinical features.
METHODS:
For this purpose, serum levels of these biochemical markers were assessed in 50 HCC patients, 30 cirrhotic patients in addition to 10 healthy subjects as a control group using enzyme linked immune-sorbent assay (ELISA).
RESULTS:
In the present study, circulating level of galectin-3, MMP-9 increased significantly in HCC as compared to the control group (P = 0.044 and 0.04, respectively). However, no significant difference was observed between cirrhotic and HCC patients (P = 0.231 and 0.193, respectively). Our study found that HCC patients with metastatic spread had a significant elevation of both serum galectin-3 and MMP-9 levels (P = 0.028 and <0.0001, respectively). In addition, galectin-3 level significantly increased in HCC patients with poor prognosis suffering from portal vein invasion (P = 0.014). Moreover, MMP-9 increased significantly with increasing stage of Barcelona-Clinic Liver Cancer Group diagnostic and treatment strategy (P = 0.01).
CONCLUSION:
MMP-9 and galectin-3 could be used as a guide for prognosis of HCC since they may play a role in HCC progression and metastasis. However, they are not useful markers for HCC diagnosis.
AuthorsNada H Eisa, Mohamed A Ebrahim, Maha Ragab, Laila A Eissa, Amal M El-Gayar
JournalJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (J Oncol Pharm Pract) Vol. 21 Issue 5 Pg. 323-30 (Oct 2015) ISSN: 1477-092X [Electronic] England
PMID24769518 (Publication Type: Journal Article)
Copyright© The Author(s) 2014.
Chemical References
  • Galectin 3
  • Matrix Metalloproteinase 9
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Hepatocellular (blood, diagnosis, pathology)
  • Case-Control Studies
  • Egypt
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Galectin 3 (blood)
  • Humans
  • Liver Cirrhosis (blood, pathology)
  • Liver Neoplasms (blood, diagnosis, pathology)
  • Male
  • Matrix Metalloproteinase 9 (blood)
  • Middle Aged
  • Neoplasm Metastasis
  • Prognosis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: